Somewhat Positive News Coverage Somewhat Unlikely to Impact RXi Pharmaceuticals (RXII) Stock Price

News stories about RXi Pharmaceuticals (NASDAQ:RXII) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. RXi Pharmaceuticals earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.9449003290826 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:

Shares of RXi Pharmaceuticals (NASDAQ RXII) opened at $0.58 on Wednesday. RXi Pharmaceuticals has a twelve month low of $0.32 and a twelve month high of $2.37.

RXi Pharmaceuticals (NASDAQ:RXII) last issued its quarterly earnings data on Wednesday, November 8th. The biotechnology company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11). During the same period in the previous year, the business posted ($0.34) EPS. equities research analysts forecast that RXi Pharmaceuticals will post -0.74 EPS for the current year.

In other news, insider Alexey Eliseev sold 176,800 shares of the stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $0.54, for a total transaction of $95,472.00. Following the completion of the sale, the insider now owns 1,100,931 shares in the company, valued at approximately $594,502.74. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 5.71% of the company’s stock.

WARNING: This story was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://stocknewstimes.com/2017/12/06/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-rxi-pharmaceuticals-rxii-stock-price.html.

RXi Pharmaceuticals Company Profile

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

Insider Buying and Selling by Quarter for RXi Pharmaceuticals (NASDAQ:RXII)

Receive News & Ratings for RXi Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply